Indication¹

OPDIVO in combination with fluoropyrimidine and platinum based combination chemotherapy is indicated for the first line treatment of adult patients with HER2 negative advanced or metastatic gastric, gastro oesophageal junction or oesophageal adenocarcinoma whose tumours express PD L1 with a combined positive score (CPS) ≥ 5.

CheckMate 649²

CheckMate 649 is a multicentre, randomised, open-label, phase 3 trial comparing nivolumab with fluoropyrimidine and platinum based combination chemotherapy for previously untreated, unresectable, advanced or metastatic gastric, GEJ, or esophageal adenocarcinomas.

The extended 3-year follow-up results on efficacy and safety were published in 2024.³

References: 

1. OPDIVO SmPC.
2. Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398(10294):27-40.